Screener
Artiva Biotherapeutics, Inc. ARTV Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Artiva Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Artiva Biotherapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:12 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338029
| Line item | SIX MONTHS ENDED JUNE 30, 2026 | SIX MONTHS ENDED JUNE 30, 2025 |
|---|---|---|
| Net loss | $(48,521) | $(41,565) |
| Adjustments to reconcile net loss to cash used in operating activities: | ||
| Depreciation and amortization | 1,358 | 1,269 |
| Stock-based compensation | 3,458 | 3,601 |
| Accretion of discounts and amortization of premiums on investments, net | (315) | (1,232) |
| Changes in operating assets and liabilities: | ||
| Other receivables (including related party amounts of $61 and $(30), respectively) | (74) | 116 |
| Prepaid expenses and other current assets | 1,850 | (3,614) |
Item 1. Financial Statements
FAQ
- What is Artiva Biotherapeutics, Inc.'s stock-based comp?
- Artiva Biotherapeutics, Inc. (ARTV) reported stock-based comp of $1.87M in Q2 2026.
- How has Artiva Biotherapeutics, Inc.'s stock-based comp changed year-over-year?
- Artiva Biotherapeutics, Inc.'s stock-based comp increased by 20.4% year-over-year, from $1.55M to $1.87M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Artiva Biotherapeutics, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude